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Future cancer immunotherapies will combine multiple
treatments to improve immune responses to cancer
through synergistic, multi-modal mechanisms. In a Phase
I clinical trial, we found that the immune response to a
peptide vaccine targeting survivin, DPX-Survivac, by
ovarian cancer patients can be improved by combination
therapy with metronomic cyclophosphamide (mCPA).
Pre-clinical studies in mice to further understand the
mechanisms of this enhanced effect demonstrated that
this improvement could be attributed to selective enrich-
ment of antigen-specific CD8+ T cells resulting in
improved immune responses detected by IFN-g ELI-
SPOT, in vivo cytotoxicity assay and improved protection
from tumors. Combination therapy was also associated
with reduced accumulation of myeloid-derived suppres-
sive cells. Efficacy of the vaccine and mCPA combination
was limited in mice with advanced tumors, yet antigen-
specific CD8+ T cells could be detected within the tumor
microenvironment by flow cytometry along with
increased expression of PD-1 by qPCR, suggesting that
the combination therapy was able to generate strong
cytotoxic T cell response but was still subject to tumor
induced suppression within the tumor microenviron-
ment. Therefore, we tested whether anti-PD1 therapy
could improve the efficacy of vaccine and mCPA combi-
nation therapy in advanced tumor models. Using
HPV16E7 expressing C3 tumor model, we found that
mice bearing advanced tumors treated with the tri-ther-
apy consisting of cancer vaccine, mCPA and anti-PD1
could more effectively eradicate tumors than those trea-
ted with single or double therapy combinations. The tri-
therapy combination was also effective in treating other
difficult to treat tumor models such as B16-F10. These
results highlight the usefulness of pre-clinical mouse
models in evaluating the mechanisms through which
multiple immune therapies can co-operate. Future work
will investigate the potential of adding anti-PD1 treat-
ment to clinical trials evaluating DPX-Survivac in combi-
nation with mCPA.
Authors’ details
1Immunovaccine Inc, Halifax, Nova Scotia, Canada. 2Ontario Institute for
Cancer Research, Toronto, Ontario, Canada. 3Queen Elizabeth II Health
Sciences, Halifax, Nova Scotia, Canada.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P130
Cite this article as: Weir et al.: Multi-modal treatment with peptide
vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal
antibody provides effective control of tumors in multiple models.
Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):P130.
1Immunovaccine Inc, Halifax, Nova Scotia, Canada
Full list of author information is available at the end of the article
Weir et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P130
http://www.immunotherapyofcancer.org/content/2/S3/P130
© 2014 Weir et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
